Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines

21 May 2010

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 20495920
DOI: 10.1007/s00280-010-1347-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell linesPMID 20495920Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.Semantic proximity Read ↗

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.Semantic proximity Read ↗

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Semantic proximity Read ↗

Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.Semantic proximity Read ↗

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell linesSemantic proximity Read ↗

Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.Semantic proximity Read ↗

Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.Semantic proximity Read ↗

Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: The importance of schedulingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.